Company Overview and News

 
Cnova's (CNV) CEO Emmanuel Grenier on Q4 2017 Results - Earnings Call Transcript

2018-02-21 seekingalpha
Greetings, and welcome to the Cnova Full Year 2017 financial results conference call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
Upvote Downvote

 
Cnova 2017 Q4 - Results - Earnings Call Slides

2018-02-20 seekingalpha
The following slide deck was published by Cnova in conjunction with their 2017 Q4 earnings call.
Upvote Downvote

 
Cnova 2016 Q4 - Results - Earnings Call Slides

2017-02-23 seekingalpha
The following slide deck was published by Cnova in conjunction with their 2016 Q4 earnings call.
Upvote Downvote

 
UPDATE 2-Brazil's GPA sharpens focus on cash-and-carry to offset downturn

2016-10-28 reuters
SAO PAULO Oct 28 GPA SA, Brazil's largest diversified retailer, said on Friday it is stepping up the opening of more cash-and-carry stores over the next year and enhancing cost-efficiencies in its appliance and e-commerce units in a bid to return to profit after six straight quarters of losses.
Upvote Downvote

 
Cnova 2016 Q3 - Results - Earnings Call Slides

2016-10-26 seekingalpha
The following slide deck was published by Cnova in conjunction with their 2016 Q3 earnings call.
Upvote Downvote

 
Cnova's (CNV) CEO Emmanuel Grenier on Q3 2016 Results - Earnings Call Transcript

2016-10-26 seekingalpha
Greeting and welcome to the Cnova Third Quarter Fiscal Year 2016 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
Upvote Downvote

 
Via Varejo reappoints CEO for next two years

2016-10-26 reuters
SAO PAULO Oct 25 Via Varejo SA, Brazil's largest appliances retailer, re-elected its chief executive officer on Tuesday as it named officers to lead the company for the next two years, according to a securities filing.
Upvote Downvote

 
E-Commerce Stocks Reporting Q3 Earnings on Oct 26: CNV, GRPN

2016-10-25 zacks
With more than 800 companies set to report results this week, including 171 S&P 500 members, the earnings season is rapidly gaining momentum. Notably, after consecutive five quarters of decline, earnings are now anticipated to show positive growth. As per the latest Zacks Earnings Preview report, overall third-quarter earnings for S&P 500 companies are anticipated to inch up 0.1% (as compared with an earlier estimate of -1%) from the year-ago quarter on revenues that are estimated to increase 1.
Upvote Downvote

 
UPDATE 1-Brazil's Via Varejo falls after Klein denies stake exit rumors

2016-10-18 reuters
SAO PAULO Oct 18 Shares in Via Varejo SA fell on Tuesday after a key minority shareholder denied speculation about a potential exit from Brazil's largest home appliance retailer.
Upvote Downvote

 
Cnova's (CNV) CEO Emmanuel Grenier on Q3 2015 Results - Earnings Call Transcript

2016-09-19 seekingalpha
Greeting, and welcome to the Cnova Third Quarter Fiscal Year 2015 Financial Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
Upvote Downvote

 
Big rip for Cnova after earnings

2016-09-17 seekingalpha
Cnova (NASDAQ:CNV) skyrockets after the company posts Q3 revenue of $869M and a loss of $0.07 per share.
Upvote Downvote

 
Cnova: Will It Ever Become Profitable? Probably Not

2016-09-17 seekingalpha
I came across this company when writing an article about Companhia Brasileira de Distribuiçăo (NYSE:CBD) a Brazilian retailer that owns 35.5% of Cnova (NASDAQ:CNV). CNV is one of the largest global e-commerce companies and its current geographies represent over 530 million people with Cdiscount sites in France, Brazil, Colombia, Ecuador, Thailand, Vietnam, Ivory Coast, Senegal, Cameroon and Belgium and operations in Brazil under the sites Extra.
Upvote Downvote

 
Cnova 2016 Q2 - Results - Earnings Call Slides

2016-09-17 seekingalpha
The following slide deck was published by Cnova in conjunction with their 2016 Q2 earnings call.
Upvote Downvote

 
Cnova's (CNV) CEO Emmanuel Grenier on Q2 2016 Results - Earnings Call Transcript

2016-09-17 seekingalpha
Greeting, and welcome to the Cnova Second Quarter 2016 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions]. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mr. Christopher Welton, of IRO. Thank you. You may begin.
Upvote Downvote

 
Brazil Is Still Far From Cheap But Some Companies Should Go On A Watch List

2016-09-17 seekingalpha
Brazil’s long term macroeconomic outlook is positive but political and financial instability are killing the markets.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

2018-04-25 - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...